AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19430944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise with slow ECC action (1-5)
Number of subjects: 9
Study 16528149 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team-based planning with nurse practitioner/physician management
Number of subjects: 1207
Study 16528149 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1207
Study 14632537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 0
Study 14632537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11076819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 18
Study 11076819 — intervention group
Group type: COMPARATOR
Intervention: No mental stress
Number of subjects: 18
Study 8996851 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (PPR) 60 mg/kg infusion every 8 hours
Number of subjects: 8
Study 8996851 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dosage pattern of Piperacillin (PPR) 60 mg/kg every 4 hours
Number of subjects: 8
Study 1444872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg for the first 48 hours, adjusted to 240 mg until the 7th day)
Number of subjects: 56
Study 1444872 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg for the first 48 hours, adjusted to 160 mg until the 7th day)
Number of subjects: 56
Study 4050895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine saline amnioinfusion
Number of subjects: 96
Study 4050895 — intervention group
Group type: COMPARATOR
Intervention: Noninfusion (control group)
Number of subjects: 96
Study 4050895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine saline amnioinfusion (in nulliparous patients)
Number of subjects: 96
Study 4050895 — intervention group
Group type: COMPARATOR
Intervention: Noninfusion (control group in nulliparous patients)
Number of subjects: 96
Study 30857954 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cryostimulation (−160 °C) for 6 minutes on the extensor-flexor muscles of the dominant arm
Number of subjects: 50
Study 30857954 — intervention group
Group type: COMPARATOR
Intervention: Control group (rested in a thermo-neutral room at 22 ± 0.5 °C)
Number of subjects: 50
Study 30857954 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cryostimulation
Number of subjects: 50
Study 30429357 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of semaglutide coformulated with sodium N‐[8‐(2‐hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
Number of subjects: 0
Study 30429357 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAC as an absorption enhancer.
Number of subjects: 0
Study 28186441 — intervention group
Group type: EXPERIMENTAL
Intervention: High HGI
Number of subjects: 7226
Study 28186441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HGI
Number of subjects: 7226
Study 28186441 — intervention group
Group type: EXPERIMENTAL
Intervention: Every percentage increase in HGI
Number of subjects: 7226
Study 25985734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir plus Ribavirin for 12 weeks
Number of subjects: 337
Study 25985734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir plus Ribavirin
Number of subjects: 337
Study 24286335 — intervention group
Group type: COMPARATOR
Intervention: GSK315234 3 mg/kg
Number of subjects: 0
Study 24286335 — intervention group
Group type: COMPARATOR
Intervention: GSK315234 0.3 mg/kg
Number of subjects: 0
Study 24286335 — intervention group
Group type: COMPARATOR
Intervention: GSK315234 6 mg/kg
Number of subjects: 0
Study 24286335 — intervention group
Group type: COMPARATOR
Intervention: GSK315234 500 mg subcutaneous
Number of subjects: 0
Study 24286335 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 21143498 — intervention group
Group type: EXPERIMENTAL
Intervention: Focussed prescribing teaching
Number of subjects: 0
Study 21143498 — intervention group
Group type: COMPARATOR
Intervention: No additional teaching (Control)
Number of subjects: 0
Study 18322078 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 16
Study 18322078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16988537 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanax XR 1 mg
Number of subjects: 24
Study 16988537 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanax XR 3 mg
Number of subjects: 24
Study 16988537 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanax XR 1 mg and 3 mg
Number of subjects: 24
Study 16988537 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanax XR
Number of subjects: 24
Study 12703834 — intervention group
Group type: EXPERIMENTAL
Intervention: fenta-7.5 (7.5 microg fentanyl)
Number of subjects: 45
Study 12703834 — intervention group
Group type: EXPERIMENTAL
Intervention: fenta-10 (10 microg fentanyl)
Number of subjects: 45
Study 12703834 — intervention group
Group type: EXPERIMENTAL
Intervention: fenta-12.5 (12.5 microg fentanyl)
Number of subjects: 45
Study 11109505 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of acenocoumarol
Number of subjects: 37
Study 11109505 — intervention group
Group type: COMPARATOR
Intervention: Gradual withdrawal of acenocoumarol
Number of subjects: 37
Study 11109505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (abrupt and gradual)
Number of subjects: 37
Study 9122904 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF at doses of 2, 5, 7.5, or 10 micrograms per kg per day for 5 days
Number of subjects: 19
Study 9122904 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF at doses of 7.5 or 10 micrograms per kg per day for both courses
Number of subjects: 19
Study 9122904 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration
Number of subjects: 19
Study 8372870 — intervention group
Group type: EXPERIMENTAL
Intervention: Active induction of labor within 5 days
Number of subjects: 200
Study 8372870 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 200
Study 3784295 — intervention group
Group type: EXPERIMENTAL
Intervention: Free dopamine (DA) concentration in CRFh
Number of subjects: 0
Study 3784295 — intervention group
Group type: EXPERIMENTAL
Intervention: Free norepinephrine (NE) concentration in CRFh
Number of subjects: 0
Study 3784295 — intervention group
Group type: COMPARATOR
Intervention: Free epinephrine (EPI) concentration in CRFh
Number of subjects: 0
Study 3784295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfo-conjugated catecholamines in CRFh
Number of subjects: 0
Study 3784295 — intervention group
Group type: COMPARATOR
Intervention: Glucuro-conjugated dopamine (DA) concentration in CRFh
Number of subjects: 0
Study 3784295 — intervention group
Group type: COMPARATOR
Intervention: Glucuro-conjugated norepinephrine (NE) concentration in CRFh
Number of subjects: 0
Study 3784295 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucuro-conjugated epinephrine (EPI) concentration in CRFh
Number of subjects: 0
Study 3784295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine, free and sulfo-conjugated catecholamines during hemodialysis
Number of subjects: 0
Study 3784295 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucuro-conjugated catecholamines during hemodialysis
Number of subjects: 0
Study 30929067 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-fortified toddler milk (21.1 µg iodine/100 g prepared drink)
Number of subjects: 135
Study 30929067 — intervention group
Group type: COMPARATOR
Intervention: Non-Fortified Milk (non-fortified cow's milk)
Number of subjects: 135
Study 30096106 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 40 U
Number of subjects: 787
Study 30096106 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 64 U
Number of subjects: 787
Study 30096106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study 30096106 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (both dosages)
Number of subjects: 787
Study 27659741 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, home‐based, medical/nursing intervention plus a rehabilitation program (telesurveillance and home-based rehabilitation)
Number of subjects: 0
Study 27659741 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 23913700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C group (13 patients)
Number of subjects: 25
Study 23913700 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 25
Study 23265404 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based coping strategies
Number of subjects: 48
Study 23265404 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive reappraisal/distraction intervention
Number of subjects: 48
Study 21453220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment
Number of subjects: 60
Study 21453220 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride desensitizer (ALLSolutions, Dentsply)
Number of subjects: 60
Study 21453220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (D/Sense Crystal, Centrix)
Number of subjects: 60
Study 21453220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of ozone/fluoride
Number of subjects: 60
Study 21453220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of ozone/oxalate
Number of subjects: 60
Study 21453220 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 60
Study 18438853 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 257
Study 18438853 — intervention group
Group type: COMPARATOR
Intervention: Control group (OASIS study, untreated with anti-TNFalpha agents)
Number of subjects: 257
Study 16290232 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal allergies
Number of subjects: 185
Study 14675857 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention using the measure of educational material acceptability (EMA)
Number of subjects: 0
Study 14675857 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention using the knowledge acquisition questionnaire (KAQ)
Number of subjects: 0
Study 11045316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal calcitriol (i.p. calcitriol)
Number of subjects: 76
Study 11045316 — intervention group
Group type: COMPARATOR
Intervention: Oral calcitriol (p.o. calcitriol)
Number of subjects: 76
Study 9363869 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin with chemotherapy and radiation therapy
Number of subjects: 0
Study 9363869 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warfarin)
Number of subjects: 0
Study 9363869 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 0
Study 1607916 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) 12 mg/m2 daily for the first 3 days, followed by consolidation with IDR 15 mg/m2 on the first day of each cycle.
Number of subjects: 218
Study 1607916 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (DNR) 45 mg/m2 daily for the first 3 days, followed by consolidation with DNR 50 mg/m2 on the first day of each cycle.
Number of subjects: 218
Study 1607916 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification (same drugs as induction, CA for 5 days and anthracycline for 2 days).
Number of subjects: 218
Study 3769194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (group A)
Number of subjects: 20
Study 3769194 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (group B)
Number of subjects: 20
Study 29558927 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First
Number of subjects: 2039
Study 26384097 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) as the only grafting material
Number of subjects: 27
Study 24837860 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 222
Study 23270519 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg extended-release guaifenesin, every 12 hours for 7 days
Number of subjects: 378
Study 23270519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 20643005 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg rocuronium (group R)
Number of subjects: 232
Study 20643005 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg atracurium (group A)
Number of subjects: 232
Study 20643005 — intervention group
Group type: COMPARATOR
Intervention: Both rocuronium and atracurium
Number of subjects: 232
Study 18319587 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-replacement diet group (MRD-G; n = 60)
Number of subjects: 90
Study 18319587 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet group (LCD-G; n = 30)
Number of subjects: 90
Study 19496195 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ablation of feeding artery (PAA) before routine RFA treatment
Number of subjects: 154
Study 19496195 — intervention group
Group type: COMPARATOR
Intervention: Routine RFA treatment
Number of subjects: 154
Study 16151471 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin 1 microg/kg
Number of subjects: 12
Study 16151471 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin 4 microg/kg
Number of subjects: 12
Study 11401006 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg/day)
Number of subjects: 10
Study 11401006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/day)
Number of subjects: 10
Study 9569080 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (5 mg/kg/day, administered q.12.h)
Number of subjects: 40
Study 9569080 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (2 mg/kg/day) plus cyclophosphamide (2 mg/kg/day)
Number of subjects: 40
Study 8045142 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone 0.5 mg/kg followed by 5 micrograms/kg/min
Number of subjects: 10
Study 8045142 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone 0.5 mg/kg followed by 10 micrograms/kg/min
Number of subjects: 10
Study 8045142 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone 1.0 mg/kg followed by 10 micrograms/kg/min
Number of subjects: 10
Study 3214958 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined short-contact coal tar and dithranol
Number of subjects: 19
Study 3214958 — intervention group
Group type: COMPARATOR
Intervention: Standard short-contact dithranol therapy
Number of subjects: 19
Study 31756059 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose bevacizumab (10 mg/kg 2-weekly)
Number of subjects: 118
Study 31756059 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose bevacizumab (5 mg/kg 2-weekly)
Number of subjects: 118
Study 31756059 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT methylated tumors
Number of subjects: 118
Study 30681617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 93
Study 30681617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 30318264 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting intracranial haemorrhage
Number of subjects: 21386
Study 30318264 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting types of intracranial haemorrhage
Number of subjects: 21386
Study 30318264 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting calvarial fractures
Number of subjects: 21386
Study 30318264 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting midline shift
Number of subjects: 21386
Study 30318264 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting mass effect
Number of subjects: 21386
Study 26704617 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 769
Study 26704617 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 769
Study 24986944 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematically aligned TKR using patient-specific guides
Number of subjects: 88
Study 24986944 — intervention group
Group type: COMPARATOR
Intervention: Mechanically aligned TKR using conventional instruments
Number of subjects: 88
Study 22309046 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (0.20 mg/kg/day)
Number of subjects: 49
Study 22309046 — intervention group
Group type: COMPARATOR
Intervention: 5 µM ADP
Number of subjects: 49
Study 22309046 — intervention group
Group type: COMPARATOR
Intervention: 5 µM TRAP
Number of subjects: 49
Study 19087105 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 215
Study 19087105 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle management (LM)
Number of subjects: 215
Study 17613606 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - aerobic and strength exercise, 3 times a week for 5 weeks
Number of subjects: 16
Study 17613606 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no change in exercise habits
Number of subjects: 16
Study 16205095 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy; mean duration: 8.8 (1.7) years
Number of subjects: 72
Study 16205095 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no GH therapy)
Number of subjects: 72
Study 11821976 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide spraying
Number of subjects: 6300
Study 11821976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit latrines
Number of subjects: 6300
Study 11821976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6300
Study 10422041 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction
Number of subjects: 69
Study 10422041 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceiving women
Number of subjects: 69
Study 10422041 — intervention group
Group type: COMPARATOR
Intervention: Nonconceiving women
Number of subjects: 69
Study 8551492 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium (50 mg titrated to 100 mg)
Number of subjects: 0
Study 8551492 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER (5 mg titrated to 10 mg)
Number of subjects: 0
Study 8551492 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER
Number of subjects: 0
Study 8551492 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium
Number of subjects: 0
Study 2255259 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported work program
Number of subjects: 0
Study 2255259 — intervention group
Group type: COMPARATOR
Intervention: Conventional workshop services
Number of subjects: 0
Study 396063 — intervention group
Group type: EXPERIMENTAL
Intervention: Saralasin (10 microgram min‐1 kg‐1)
Number of subjects: 3
Study 396063 — intervention group
Group type: EXPERIMENTAL
Intervention: Saralasin (40 microgram min‐1 kg‐1)
Number of subjects: 3
Study 396063 — intervention group
Group type: COMPARATOR
Intervention: Low salt intake (15 mmol of Na+/day)
Number of subjects: 3
Study 396063 — intervention group
Group type: COMPARATOR
Intervention: High salt intake (290 mmol of Na+/day)
Number of subjects: 3
Study 396063 — intervention group
Group type: EXPERIMENTAL
Intervention: Saralasin (both doses)
Number of subjects: 3
Study 31486420 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-laser myringotomy on the 3rd day of hospital treatment
Number of subjects: 172
Study 31486420 — intervention group
Group type: COMPARATOR
Intervention: CO2-laser myringotomy on the 7th day of hospital treatment
Number of subjects: 172
Study 28129268 — intervention group
Group type: EXPERIMENTAL
Intervention: Allgöwer-Donati
Number of subjects: 30
Study 28129268 — intervention group
Group type: COMPARATOR
Intervention: Vertical mattress
Number of subjects: 30
Study 26418813 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based counselling strategy
Number of subjects: 24381
Study 23823612 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL)
Number of subjects: 623
Study 23823612 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope (DL)
Number of subjects: 623
Study 21967819 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800
Study 21967819 — intervention group
Group type: COMPARATOR
Intervention: PES
Number of subjects: 1800
Study 19480558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dosing of PF-219061
Number of subjects: 0
Study 17461981 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg (SIMVA)
Number of subjects: 60
Study 17461981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of simvastatin 40 mg and ezetimibe 10 mg (EZE/SIMVA)
Number of subjects: 60
Study 17461981 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering drugs (NLLD)
Number of subjects: 60
Study 15465744 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants with whey:casein 60:40
Number of subjects: 18
Study 15465744 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants with whey:casein 40:60
Number of subjects: 18
Study 15465744 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants with whey:casein 20:80
Number of subjects: 18
Study 15465744 — intervention group
Group type: COMPARATOR
Intervention: Infants fed mother's milk
Number of subjects: 18
Study 15465744 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 18
Study 12086558 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 20
Study 12086558 — intervention group
Group type: COMPARATOR
Intervention: Literature review of concentration‐effect relationships
Number of subjects: 20
Study 9703185 — intervention group
Group type: EXPERIMENTAL
Intervention: Queckenstedt's manoeuvre (cranial venous dilatation)
Number of subjects: 20
Study 9703185 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure (equal pressure applied to the lateral aspect of the neck)
Number of subjects: 20
Study 8010332 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (300 mg daily for 30 days)
Number of subjects: 95
Study 8010332 — intervention group
Group type: COMPARATOR
Intervention: Wheat germ oil capsules (control group)
Number of subjects: 95
Study 2690721 — intervention group
Group type: EXPERIMENTAL
Intervention: High compression stockings (40 mmHg) after varicose vein surgery
Number of subjects: 0